Geron (FRA:GON) Inventories, Work In Process: €85.7 Mil (As of Mar. 2026)


FRA:GON Geron Corp FRA:GON
39 GF Score
Price €1.18
GF Value €6.00
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Geron Inventories, Work In Process?

Geron FRA:GON -2.81% 39 Inventories, Work In Process is €85.7 Mil as of Mar. 2026. GuruFocus rates FRA:GON with a GF Score™ of 39/100 and a GF Value™ of €6.00 (Possible Value Trap). The stock has 4 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Geron's work in process for the quarter that ended in Mar. 2026 was €85.7 Mil.

Geron Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Geron's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Geron Inventories, Work In Process Chart

Geron Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 28.74 78.54

Geron Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.32 40.76 53.81 78.54 85.74
FRA:GON
39GF Score
Geron Corp FRA:GON
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Geron Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of €85.7 Mil mean?
Geron (FRA:GON) has a Inventories, Work In Process of €85.7 Mil as of Mar. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Geron and its competitors.
Is Geron's Inventories, Work In Process too high?
Geron's current Inventories, Work In Process is €85.7 Mil. Overall, Geron has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Geron's Inventories, Work In Process compare to SPRY and PHAT?
Geron's Inventories, Work In Process of €85.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Biotechnology company?
A good Inventories, Work In Process depends on the Biotechnology industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Geron and its competitors. Geron's current Inventories, Work In Process is €85.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geron stock overvalued right now?
Based on GuruFocus' analysis, Geron (FRA:GON) is currently considered Possible Value Trap. The stock's GF Value™ is €6.00, compared to a current price of €1.18 — trading 80.4% below its estimated fair value. The current Inventories, Work In Process is €85.7 Mil. Geron's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Geron (FRA:GON), the current Inventories, Work In Process is €85.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Geron (FRA:GON) Overvalued in 2026?

Based on GuruFocus' analysis, Geron stock appears to be undervalued. The current stock price of €1.18 is trading 80.4% below its estimated GF Value™ of €6.00. GuruFocus considers Geron to be Possible Value Trap.

Key valuation signals for FRA:GON:

  • Inventories, Work In Process: €85.7 Mil
  • GF Value™: €6.00 vs. price of €1.18 (80.4% below fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the FRA:GON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Geron Business Description

Address 919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.
39GF Score

Get the complete analysis for FRA:GON

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.18
Price
€6.00
GF Value